All In Biotech

Drug Trial Radar · NCT00662038

Open-Label Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)

An Open-Label Extension Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Last checked: Nov 20, 2026Latest source record: Mar 29, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,058

Actual

Start

Aug 2008

Primary completion

Feb 2016

Study completion Feb 2016

Sponsor

Lead sponsor
Genentech, Inc.Roche (Genentech) (RHHBY)
Sponsor type
Industry
Collaborators
Hoffmann-La Roche
First posted
Apr 21, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 40 years, up to 84 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multi-center, extension study for patients with IPF who complete a qualifying InterMune clinical trial of pirfenidone. The purpose of this study is to obtain additional safety data for pirfenidone 2403 mg/day in patients with IPF who complete a qualifying InterMune clinical trial of pirfenidone.

Conditions

  • Idiopathic Pulmonary Fibrosis

Interventions

  • pirfenidoneDrug

    Pirfenidone, 2403 mg/d, administered as 801-mg doses, three times daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Adverse EventsTime frame: 7.5 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Genentech, Inc.

    South San Francisco, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.